About Speratum Biopharma, Inc.
Speratum Biopharma, Inc. (“Speratum”) is an innovative biotechnology company focused on research and development of targeted nucleic acid delivery systems and oligonucleotide therapeutics. Speratum’s Nano-inTM and No-Pass MimicTM technologies have broad applicability as platform technologies for nucleic acid drug delivery and oligonucleotide administration in vitro and in vivo, and have been out-licensed for multiple therapeutic modalities, including skin diseases therapeutics and antiviral treatments.

Speratum is currently in final pre-clinical stages of development for its first therapeutic, a small RNA tumor suppressor against pancreatic, ovarian, and other cancers.

The company was founded in 2014 with technologies licensed from Baylor College of Medicine. Since then, Speratum has continued to innovate with with best-in class, proprietary technologies to generate a ground-breaking oligonucleotide, nucleic acid, and cell therapy platform.

For more information about Speratum Biopharma, please e-mail info@speratum.com

OUR TEAM

Speratum Biopharma is comprised of a team of talented scientists, clinicians, and executives committed to developing breakthrough science from bench to bedside.


user


Christian Marín-Müller

MS - PhD

Founder and Chief Executive Officer
Co-inventor of Speratum’s technologies




user


Osvaldo Vega-Martínez

MS

Chief Science Officer
Co-inventor of Speratum’s technologies




user


Allan Boruchowicz

BS

Founder and Managing
Director Carao Ventures



OUR TECHNOLOGIES

Speratum Biopharma, Inc. is an innovative biotechnology company focused on pre-clinical research and development of oligonucleotide therapeutics for the treatment of cancer. The company’s primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids.

See our Publications